Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Radnor, PA, US. The stock last traded at $25.86, down 2.75% on the session, giving a market capitalisation of $2.28B. On trailing twelve-month figures it carries a trailing P/E of -6.10, a net margin of 0.0%. Its beta of 0.68 implies it has historically moved less than the broad market.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Mineralys Therapeutics, Inc. is most often compared with the following Healthcare names: